Shuzo Yoshida
Overview
Explore the profile of Shuzo Yoshida including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
296
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ishida T, Yoshida S, Fujiki Y, Hata K, Kotani T, Takeuchi T
Arch Osteoporos
. 2021 Feb;
16(1):39.
PMID: 33624165
Introduction: The aim of this study was to evaluate the clinical efficacy and safety of denosumab in patients with rheumatic diseases and glucocorticoid-induced osteoporosis (GIOP) refractory to previous osteoporosis treatment....
2.
Kimura Y, Yoshida S
Mod Rheumatol Case Rep
. 2020 Oct;
4(2):168-170.
PMID: 33086993
We report the case of a 69-year-old man with a 38-year history of rheumatoid arthritis (RA), who developed Felty's syndrome, successful treatment with abatacept (ABT). He was treated with etanercept...
3.
Yoshida S, Kimura Y
Ther Apher Dial
. 2020 May;
25(2):249-251.
PMID: 32445226
No abstract available.
4.
Yoshida S, Kimura Y
Int J Rheum Dis
. 2020 May;
23(6):837-839.
PMID: 32406191
No abstract available.
5.
Tokai N, Yoshida S, Kotani T, Yoshikawa A, Kimura Y, Fujiki Y, et al.
PLoS One
. 2019 Jan;
14(1):e0211750.
PMID: 30699195
[This corrects the article DOI: 10.1371/journal.pone.0202601.].
6.
Suzuka T, Kotani T, Takeuchi T, Fujiki Y, Hata K, Yoshida S, et al.
Int J Rheum Dis
. 2018 Nov;
22(2):303-313.
PMID: 30398034
Objectives: We assessed the efficacy and safety of combination therapy with glucocorticoids and high-trough level tacrolimus (TAC) for the treatment of acute/subacute interstitial pneumonia (A/SIP) in patients with dermatomyositis (DM)....
7.
Yoshida S, Kotani T, Kimura Y, Matsumura Y, Yoshikawa A, Tokai N, et al.
Int J Rheum Dis
. 2018 Sep;
22(1):81-89.
PMID: 30168272
Aim: To investigate whether remission can be sustained for rheumatoid arthritis (RA) patients after tapering abatacept (ABT). Method: All patients were naïve to biological disease-modifying anti-rheumatic drugs (bDMARDs) and in...
8.
Tokai N, Yoshida S, Kotani T, Yoshikawa A, Kimura Y, Fujiki Y, et al.
PLoS One
. 2018 Aug;
13(8):e0202601.
PMID: 30138480
Objective: The aim of this study was to clarify whether serum matrix metalloproteinase 3 (MMP-3) levels are associated with an effect of iguratimod as add-on therapy to biological DMARDs (bDMARDs)...
9.
Hashimoto M, Furu M, Yamamoto W, Fujimura T, Hara R, Katayama M, et al.
Arthritis Res Ther
. 2018 Aug;
20(1):165.
PMID: 30075810
Background: Clinical remission can be maintained after the discontinuation of biological disease-modifying antirheumatic drugs (bDMARDs) in some patients with rheumatoid arthritis (RA) (bDMARD-free remission (BFR)). It is unknown which bDMARD...
10.
Ebina K, Hashimoto M, Yamamoto W, Ohnishi A, Kabata D, Hirano T, et al.
PLoS One
. 2018 Mar;
13(3):e0194130.
PMID: 29543846
The purpose of this study was to evaluate the retention and discontinuation reasons of seven biological disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting of patients with rheumatoid arthritis (RA)....